Tomoko Yamamoto Funazo (Tomoko Funazo)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 3

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Scientific reports

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Yamamoto Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masatsugu Hamaji, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer. Molecular cancer therapeutics (2023)
Takahiro Tsuji, Hiroaki Ozasa, Mitsuyoshi Ueda, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature communications 11 (1) (2020)
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific reports 9 (1) (2019)